Talimogene laherparepvec, a new oncolytic immunotherapy, has been recently approved for the treatment of melanoma. Using a murine version of the virus, we characterized local and systemic antitumor immune responses driving efficacy in murine syngeneic models. The activity of talimogene laherparepvec was characterized against melanoma cell lines using an viability assay. Efficacy of OncoVEX (talimogene laherparepvec with the mouse granulocyte-macrophage colony-stimulating factor transgene) alone or in combination with checkpoint blockade was characterized in A20 and CT-26 contralateral murine tumor models. CD8 depletion, adoptive T-cell transfers, and Enzyme-Linked ImmunoSpot assays were used to study the mechanism of action (MOA) of systemic immune responses. Treatment with OncoVEX cured all injected A20 tumors and half of contralateral tumors. Viral presence was limited to injected tumors and was not responsible for systemic efficacy. A significant increase in T cells (CD3/CD8) was observed in injected and contralateral tumors at 168 hours. analyses showed these cytotoxic T lymphocytes were tumor-specific. Increased neutrophils, monocytes, and chemokines were observed in injected tumors only. Importantly, depletion of CD8 T cells abolished all systemic efficacy and significantly decreased local efficacy. In addition, immune cell transfer from OncoVEX-cured mice significantly protected from tumor challenge. Finally, combination of OncoVEX and checkpoint blockade resulted in increased tumor-specific CD8 anti-AH1 T cells and systemic efficacy. The data support a dual MOA for OncoVEX that involves direct oncolysis of injected tumors and activation of a CD8-dependent systemic response that clears injected and contralateral tumors when combined with checkpoint inhibition. .

Pertuzumab is a monoclonal antibody that binds to HER2 and is used in combination with another HER2–specific monoclonal antibody, trastuzumab, for the treatment of HER2+ metastatic breast cancer. Pertuzumab binds to an HER2 binding site distinct from that of trastuzumab, and its affinity is enhanced when trastuzumab is present. We aim to exploit this enhanced affinity of pertuzumab for its HER2 binding epitope and adapt this antibody as a PET imaging agent by radiolabeling with 89Zr to increase the sensitivity of HER2 detection in vivo. Here, we investigate the biodistribution of 89Zr-pertuzumab in HER2–expressing BT-474 and HER2–nonexpressing MDA-MB-231 xenografts to quantitatively assess HER2 expression in vivo. In vitro cell binding studies were performed resulting in retained immunoreactivity and specificity for HER2–expressing cells. In vivo evaluation of 89Zr-pertuzumab was conducted in severely combined immunodeficient mice, subcutaneously inoculated with BT-474 and MDA-MB-231 cells. 89Zr-pertuzumab was systemically administered and imaged at 7 days postinjection (p.i.) followed by terminal biodistribution studies. Higher tumor uptake was observed in BT-474 compared to MDA-MB-231 xenografts with 47.5 ± 32.9 and 9.5 ± 1.7% ID/g, respectively at 7 days p.i (P = 0.0009) and blocking studies with excess unlabeled pertuzumab showed a 5-fold decrease in BT-474 tumor uptake (P = 0.0006), confirming the in vivo specificity of this radiotracer. Importantly, we observed that the tumor accumulation of 89Zr-pertuzumab was increased in the presence of unlabeled trastuzumab, at 173 ± 74.5% ID/g (P = 0.01). Biodistribution studies correlate with PET imaging quantification using max SUV (r = 0.98, P = 0.01). Collectively, these results illustrate that 89Zr-pertuzumab as a PET imaging agent may be beneficial for the quantitative and noninvasive assessment of HER2 expression in vivo especially for patients undergoing trastuzumab therapy.

No abstract

Positron emission tomography, with its high sensitivity and resolution, is growing rapidly as an imaging technology for the diagnosis of many disease states. The success of this modality is reliant on instrumentation and the development of effective and novel targeted probes. Initially, research in this area was focused on what we will define in this article as 'standard' PET isotopes (carbon-11, nitrogen-13, oxygen-15 and fluorine-18), but the short half-lives of these isotopes limit radiopharmaceutical development to those that probe rapid biological processes. To overcome these limitations, there has been a rise in nonstandard isotope probe development in recent years. This review focuses on the biological probes and processes that have been examined, in additiom to the preclinical and clinical findings with nonstandard radiometals: copper-64, zirconium-89, and yttrium-86.

The reaction in water of Cu(NO(3))(2)·2.5H(2)O with 2,2'-bipyridine (bipy), 1,10-phenanthroline (phen), or 1,10-phenanthroline-5-amine (phenam), and sodium pyrophosphate (Na(4)P(2)O(7)), at various pHs, afforded three new copper(II)-pyrophosphate complexes, namely, {[Cu(bipy)(cis-H(2)P(2)O(7))](2)}·3H(2)O (1a), {[Cu(phen)(H(2)O)](4)(HP(2)O(7))(2)}(ClO(4))(2)·4H(2)O (2), and {[Cu(2)(phenam)(2)(P(2)O(7))](2)·25H(2)O}(n) (3). A solvent free crystalline phase of 1a was also isolated with formula {[Cu(bipy)(trans-H(2)P(2)O(7))](2)} (1b), which can be regarded as a pseudo-polymorph of 1a. Single crystal X-ray analyses revealed these compounds to have uncommon molecular architectures, with 3 being an unprecedented pyrophosphate-containing two-dimensional (2D) polymer. Compounds 1a/1b and 2 are discrete di- and tetra-nuclear complexes, respectively. The cationic {[Cu(phen)(H(2)O)](4)(HP(2)O(7))(2)}(2+) unit in 2 presents a unique quasi-flat structure, held together by solely in-plane pyrophosphate bridging modes (short O(eq)-P-O(eq) and long O(eq)-P-O-P-O(eq) pathways), a coordination arrangement also not previously reported. A different tetranuclear copper(II)-pyrophosphate arrangement is found in 3, with two classically bridged dimers (O(eq)-P-O(eq) pathway) joined together by auxiliary equatorial-axial μ-O pyrophosphate bridges. Here, the bidimensionality is reached through bridging phenam ligands, which provide further inter-"tetramer" metal-metal connections [(N,N')(eq)-(N'')(ax) pathway], leading to the formation of an expanded covalent network based on the [Cu(2)(phenam)(2)(P(2)O(7))](2) moiety. Variable-temperature magnetic susceptibility measurements on polycrystalline samples of 2 and 3 revealed net antiferromagnetic coupling between metal centers with J(2a) = -7.9(2) cm(-1), J(2b) = -46.9(3) cm(-1), J(2c) = 0 cm(-1) in 2 (H = -J(2a)[S(Cu(1))·S(Cu(2)) + S(Cu(1a))·S(Cu(2a))] - J(2b)[S(Cu(1))·S(Cu(2a)) + S(Cu(1a))·S(Cu(2))] - J(2c)S(Cu(2))·S(Cu(2a))), and J(3a) = -87.9(2) cm(-1), J(3b) = -5(1) cm(-1) and J(3c) = +5(3) cm(-1) in 3 (H = -J(3a)[S(Cu(1))·S(Cu(2)) + S(Cu(1a))·S(Cu(2a))] - J(3b)[S(Cu(1))·S(Cu(2a)) + S(Cu(1a))·S(Cu(2))] - J(3c)S(Cu(2))·S(Cu(2a))). For 1a, a net ferromagnetic coupling is observed with J(1a) = +0.86(1) cm(-1) (H = -J S(A)·S(B) + S(A)·D· S(B) + βH (g(A)S(A) + g(B)S(B)). This is the first example of ferromagnetic coupling in pyrophosphate-complexes reported to date. A structure-function correlation study focusing on magnetic exchange across the observed diverse pyrophosphate-bridges is described with density functional theory (DFT) calculations included to support the stated observations.